Streamline Health Solutions (STRM) 10-Q 12 Sep 24 2025 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jul. 31, 2024	Sep. 09, 2024
Document Information [Line Items]
Entity Central Index Key	0001008586
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS INC.
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 31, 2024
Document Transition Report	false
Entity File Number	000-28132
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1455414
Entity Address, Address Line One	2400 Old Milton Pkwy., Box 1353
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30009
City Area Code	888
Local Phone Number	997-8732
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	STRM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		63,324,103

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jul. 31, 2024	Jan. 31, 2024
Current assets:
Cash and cash equivalents	$ 3,536,000	$ 3,190,000
Accounts receivable, net of allowance for credit losses of $59,000 and $86,000, respectively	2,521,000	4,237,000
Contract receivables	969,000	780,000
Prepaid and other current assets	659,000	629,000
Total current assets	7,685,000	8,836,000
Non-current assets:
Property and equipment, net of accumulated amortization of $316,000 and $291,000 respectively	64,000	88,000
Capitalized software development costs, net of accumulated amortization of $8,848,000 and $7,960,000, respectively	5,403,000	5,798,000
Intangible assets, net of accumulated amortization of $4,837,000 and $4,019,000, respectively	11,253,000	12,071,000
Goodwill	13,276,000	13,276,000
Other	1,344,000	1,666,000
Total non-current assets	31,340,000	32,899,000
Total assets	39,025,000	41,735,000
Current liabilities:
Accounts payable	1,413,000	1,253,000
Accrued expenses	1,948,000	2,023,000
Current portion of term loan	2,000,000	1,500,000
Deferred revenues	6,591,000	7,112,000
Acquisition earnout liability	577,000	1,794,000
Total current liabilities	12,529,000	13,682,000
Non-current liabilities:
Term loan, net of current portion and deferred financing costs	6,611,000	7,566,000
Line of credit	0	1,500,000
Notes payable, net of deferred financing costs	3,853,000	0
Deferred revenues, less current portion	134,000	173,000
Total non-current liabilities	10,598,000	9,239,000
Total liabilities	23,127,000	22,921,000
Commitments and contingencies – Note 8
Stockholders’ equity:
Common stock, $0.01 par value per share, 85,000,000 shares authorized; 63,307,832 and 58,945,498 shares issued and outstanding, respectively	633,000	590,000
Additional paid in capital	136,506,000	133,923,000
Accumulated deficit	(121,241,000)	(115,699,000)
Total stockholders’ equity	15,898,000	18,814,000
Total liabilities and stockholders’ equity	$ 39,025,000	$ 41,735,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jul. 31, 2024	Jan. 31, 2024
Allowance for credit losses	$ 59,000	$ 86,000
Accumulated amortization	316,000	291,000
Capitalized software accumulated amortization	8,848,000	7,960,000
Intangible assets, accumulated amortization	$ 4,837,000	$ 4,019,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	85,000,000	85,000,000
Common stock, shares issued (in shares)	63,307,832	58,945,498
Common stock, shares outstanding (in shares)	63,307,832	58,945,498

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations - USD ($)		3 Months Ended		6 Months Ended
		Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Revenues:
Total revenues		$ 4,476,000	$ 5,770,000	$ 8,807,000	$ 11,102,000
Operating expenses:
Selling, general and administrative expense		2,989,000	4,116,000	6,181,000	7,957,000
Research and development		1,324,000	1,305,000	2,435,000	3,006,000
Total operating expenses		6,691,000	8,368,000	13,271,000	16,696,000
Operating loss		(2,215,000)	(2,598,000)	(4,464,000)	(5,594,000)
Other (expense) income:
Interest expense		(496,000)	(267,000)	(961,000)	(515,000)
Valuation adjustments		(91,000)	359,000	(115,000)	723,000
Other		(1,000)	(1,000)	(2,000)	31,000
Loss before income taxes		(2,803,000)	(2,507,000)	(5,542,000)	(5,355,000)
Income tax expense		0	(8,000)	0	(61,000)
Net loss		$ (2,803,000)	$ (2,515,000)	$ (5,542,000)	$ (5,416,000)
Basic and Diluted Earnings Per Share:
Net loss per common share – basic and diluted (in dollars per share)		$ (0.05)	$ (0.04)	$ (0.09)	$ (0.1)
Weighted average number of common shares – basic and diluted (in shares)	[1],[2]	60,110,178	56,357,684	59,167,134	56,164,282
Software as a Service [Member]
Revenues:
Total revenues		$ 3,078,000	$ 3,531,000	$ 5,801,000	$ 6,706,000
Operating expenses:
Cost of goods and services		1,495,000	1,893,000	2,844,000	3,482,000
Maintenance [Member]
Revenues:
Total revenues		883,000	1,100,000	1,773,000	2,257,000
Operating expenses:
Cost of goods and services		43,000	32,000	84,000	121,000
Professional Fees and Licenses [Member]
Revenues:
Total revenues		515,000	1,139,000	1,233,000	2,139,000
Operating expenses:
Cost of goods and services		$ 840,000	$ 1,022,000	$ 1,727,000	$ 2,130,000
[1]Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and six months ended July 31, 2024, diluted earnings per share excludes 66,000 outstanding stock options, 3,467,600 unvested restricted shares of common stock, and 3,555,499 shares of common stock issuable through the exercise of warrants. For the three and six months ended July 31, 2023, diluted earnings per share excludes 618,958 outstanding stock options and 2,484,071 unvested restricted shares of common stock.[2]Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2024 and 2023, there were 3,467,600 and 2,655,831 unvested restricted shares of common stock outstanding, respectively.

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	0
Balance (in shares) at Jan. 31, 2023					57,567,210
Balance (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	$ 0	$ 0	$ 36,000	$ 36,000
Balance at Jan. 31, 2023					$ 576,000	$ 131,973,000	$ (97,038,000)	$ 35,511,000
Restricted stock issued (in shares)					1,185,927
Restricted stock issued					$ 12,000	(12,000)	0	0
Restricted stock forfeited (in shares)					(28,400)
Restricted stock forfeited					$ (1,000)		0	0
Surrender of shares (in shares)					(88,326)
Surrender of shares					$ (1,000)	(178,000)	0	(179,000)
Share-based compensation					0	595,000	0	595,000
Net loss					$ 0	0	(2,901,000)	(2,901,000)
Restricted stock forfeited						(1,000)
Balance (in shares) at Apr. 30, 2023					58,636,411
Balance at Apr. 30, 2023					$ 586,000	132,379,000	(99,903,000)	33,062,000
Balance (in shares) (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	0
Balance (in shares) at Jan. 31, 2023					57,567,210
Balance (Accounting Standards Update 2016-13 [Member]) at Jan. 31, 2023	$ 0	$ 0	$ 36,000	$ 36,000
Balance at Jan. 31, 2023					$ 576,000	131,973,000	(97,038,000)	35,511,000
Net loss								(5,416,000)
Balance (in shares) at Jul. 31, 2023					58,895,071
Balance at Jul. 31, 2023					$ 589,000	132,933,000	(102,418,000)	31,104,000
Balance (in shares) at Apr. 30, 2023					58,636,411
Balance at Apr. 30, 2023					$ 586,000	132,379,000	(99,903,000)	33,062,000
Restricted stock issued (in shares)					385,720
Restricted stock issued					$ 4,000	(4,000)	0	0
Restricted stock forfeited (in shares)					(77,000)
Restricted stock forfeited					$ (1,000)		0	0
Surrender of shares (in shares)					(50,060)
Surrender of shares					$ 0	(73,000)	0	(73,000)
Share-based compensation					0	630,000	0	630,000
Net loss					$ 0	0	(2,515,000)	(2,515,000)
Restricted stock forfeited						(1,000)
Balance (in shares) at Jul. 31, 2023					58,895,071
Balance at Jul. 31, 2023					$ 589,000	132,933,000	(102,418,000)	31,104,000
Balance (in shares) at Jan. 31, 2024					58,945,498
Balance at Jan. 31, 2024					$ 590,000	133,923,000	(115,699,000)	18,814,000
Restricted stock issued (in shares)					1,215,000
Restricted stock issued					$ 11,000	(11,000)	0	0
Restricted stock forfeited (in shares)					(48,350)
Restricted stock forfeited					$ 0	0	0	0
Surrender of shares (in shares)					(139,105)
Surrender of shares					$ (1,000)	(66,000)	0	(67,000)
Share-based compensation					$ 0	529,000	0	529,000
Issuance of common stock (in shares)					1,852,544
Issuance of common stock					$ 17,000	753,000	0	770,000
Offering expenses					0	(4,000)	0	(4,000)
Net loss					$ 0	0	(2,739,000)	(2,739,000)
Balance (in shares) at Apr. 30, 2024					61,825,587
Balance at Apr. 30, 2024					$ 617,000	135,124,000	(118,438,000)	17,303,000
Balance (in shares) at Jan. 31, 2024					58,945,498
Balance at Jan. 31, 2024					$ 590,000	133,923,000	(115,699,000)	18,814,000
Net loss								(5,542,000)
Balance (in shares) at Jul. 31, 2024					63,307,832
Balance at Jul. 31, 2024					$ 633,000	136,506,000	(121,241,000)	15,898,000
Balance (in shares) at Apr. 30, 2024					61,825,587
Balance at Apr. 30, 2024					$ 617,000	135,124,000	(118,438,000)	17,303,000
Restricted stock issued (in shares)					1,706,517
Restricted stock issued					$ 17,000	(17,000)	0	0
Restricted stock forfeited (in shares)					(282,250)
Restricted stock forfeited					$ (3,000)		0	0
Surrender of shares (in shares)					(51,777)
Surrender of shares						(11,000)	0	(10,000)
Share-based compensation					$ 0	571,000	0	571,000
Issuance of common stock					0	0	0	0
Net loss					0	0	(2,803,000)	(2,803,000)
Restricted stock forfeited						(3,000)
Surrender of shares					$ (1,000)
Cashless exercise of warrants (in shares)					109,755
Cashless exercise of warrants					$ 1,000	(1,000)	0	0
Warrant liability reclassification					$ 0	837,000	0	837,000
Balance (in shares) at Jul. 31, 2024					63,307,832
Balance at Jul. 31, 2024					$ 633,000	$ 136,506,000	$ (121,241,000)	$ 15,898,000

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Net loss	$ (5,542,000)	$ (5,416,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,290,000	2,134,000
Accrued interest expense - notes payable	326,000	0
Valuation adjustments	115,000	(723,000)
Benefit for deferred income taxes	0	43,000
Share-based compensation expense	1,032,000	1,109,000
Provision for credit losses	(58,000)	0
Changes in assets and liabilities:
Accounts and contract receivables	1,585,000	4,985,000
Other assets	(71,000)	(146,000)
Accounts payable	78,000	31,000
Accrued expenses and other liabilities	(75,000)	(1,361,000)
Deferred revenue	(560,000)	(1,592,000)
Net cash used in operating activities	(880,000)	(936,000)
Cash flows from investing activities:
Purchases of property and equipment	0	(47,000)
Capitalization of software development costs	(426,000)	(1,026,000)
Net cash used in investing activities	(426,000)	(1,073,000)
Cash flows from financing activities:
Repayment of bank term loan	(500,000)	(250,000)
Repayment of line of credit	(1,500,000)	0
Proceeds from issuance of common stock	100,000	0
Proceeds from notes payable	4,400,000	0
Payments of acquisition earnout liabilities	(686,000)	0
Payments for deferred financing costs	(86,000)	0
Repurchase of common shares to satisfy employee tax withholding	(77,000)	(252,000)
Other	1,000	0
Net cash provided (used in) by financing activities	1,652,000	(502,000)
Net increase (decrease) in cash and cash equivalents	346,000	(2,511,000)
Cash and cash equivalents at beginning of period	3,190,000	6,598,000
Cash and cash equivalents at end of period	$ 3,536,000	$ 4,087,000

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	1 — BASIS OF PRESENTATION Streamline Health Solutions, Inc. and each of its wholly-owned subsidiaries, Streamline Health, LLC, Avelead Consulting, LLC, Streamline Consulting Solutions, LLC and Streamline Pay & Benefits, LLC, (collectively, unless the context requires otherwise, “we,” “us,” “our,” “Streamline,” or the “Company”), operate in one The accompanying unaudited condensed consolidated financial statements have been prepared by us pursuant to the rules and regulations applicable to quarterly reports on Form 10 not 10 three six July 31, 2024 not may January 31, 2025. The Company has one one All amounts in the condensed consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated. All references to a fiscal year refer to the fiscal year commencing February 1 January 31 Going Concern The Company’s financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. To date, the Company has not twelve may not twelve one In view of these matters, continuation as a going concern is dependent upon the Company’s ability to achieve cash from operations and raise additional debt or equity capital to fund its ongoing operations. As of July 31, 2024, no The financial statements do not may not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Our significant accounting policies are presented in “Note 2 10 2023. 10 Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates. Reclassification Certain amounts for the three six July 31, 2023 three six July 31, 2023, three six July 31, 2023 Fair Value of Financial Instruments The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one three Level 1: Level 2: Level 3: not The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. 3 April 30, 2024. The table below provides information on the fair value of our liabilities on a recurring basis: Quoted Significant Prices in Other Significant Active Observable Unobservable Total Fair Markets Inputs Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2024 Acquisition earnout liability (1) $ 1,794,000 $ — $ — $ 1,794,000 ( 1 On March 27, 2024, 3 no 3 3. The table below provides the Level 3 six July 31, 2024. no 3 three July 31, 2024. Six-months ended July 31, 2024 Beginning balance $ 1,794,000 Settlement – common stock (690,000 ) Settlement – cash (447,000 ) Realized loss 159,000 Transfer out (817,000 ) Ending balance $ — The value of the Company’s acquisition earnout liability at July 31, 2024, October 31, 2024. The fair value of the Company’s term loan under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan ( August 2021) July 31, 2024 January 31, 2024 Prime Rate July 31, 2024 January 31, 2024, The estimated fair value of the Company’s notes payable under its private placement notes payables was determined through an analysis of the interest rate spread from the date of closing of the private placement ( February 7, 2024) July 31, 2024. 30 1 10 February 7, 2024 ( 30 July 31, 2024 The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input uses the warrant strike prices of $0.38 $0.39, February 7, 2024, April 30, 2024, May 7, 2024) 48 Using this methodology, the Company recorded an opening warrant liability of $881,000 as of February 7, 2024. April 30, 2024 May 7, 2024 three six July 31, 2024, May 7, 2024, Revenue Recognition We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers may Disaggregation of Revenue The following table provides information about disaggregated revenue by type and nature of revenue stream: Three Months Ended Six Months Ended July 31, 2024 July 31, 2023 July 31, 2024 July 31, 2023 Over time revenue $ 4,476,000 $ 5,770,000 $ 8,672,000 $ 11,028,000 Point in time revenue — — 135,000 74,000 Total revenue $ 4,476,000 $ 5,770,000 $ 8,807,000 $ 11,102,000 The Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses as point in time revenue. Contract Receivables and Deferred Revenues The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not . During the three six July 31, 2024 , the Company recognized approximately $1,795,000 and $4,625,000, respectively, in revenue from deferred revenues outstanding as of January 31, 2024 . Revenue allocated to remaining performance obligations was $ as of July 31, 2024 , of which the Company expects to recognize approximately 43% over the next 12 months and the remainder thereafter. Deferred costs (costs to fulfill a contract and contract acquisition costs) The Company defers th e direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of July 31, 2024 and January 31, 2024 , the Company had deferred costs of $55,000 and $77,000, r on of $136,000 and $102,000, r s $33,000 and $34,000 fo six July 31, 2024 2023 three July 31, 2024 2023, Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one As of July 31, 2024 and January 31, 2024 , deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $1,279,000 and $1,461,000, respectively. Amortization expense associated with deferred sales commissions, which is included in selling, general and administrative expense in the condensed consolidated statements of operations, was $169,000 and $125,000 for the three July 31, 2024 2023 , respectively. For the six July 31, 2024 2023, Allowance for Credit Losses The Company estimates current expected credit losses based on historical credit loss rates and applied an increase to account for future economic conditions. The changes in the Company’s allowance for credit losses is as follows: January 31, 2024 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2024 Allowance for credit losses $ 86,000 $ — (58,000 ) 31,000 $ 59,000 January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2023 Allowance for credit losses $ 132,000 $ (36,000 ) $ — $ — $ 96,000 Equity Awards The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three six July 31, 2024, three six July 31, 2023. The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards. The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three six July 31, 2024, three six July 31, 2023, three three six July 31, 2024, three six July 31, 2023, Market-Based Awards For awards with a market condition, the Company adjusts the grant date fair value for the condition. The Company used separate Monte Carlo valuation models, as of the grant date, to determine the expected length and fair value of this particular award. Both models used the Company's historical equity volatility, current stock price, and hurdle target price for vesting. The service period model also included an assumption for the Company's 10 On July 18, 2024, Warrants The Company reviews the specific terms for its warrants and applies the authoritative FASB guidance under ASC topics 480 , 480” 815 , 815” 480 , 480 , 815 , For the issued or modified warrants that qualify for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not not not not 6 The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not July 31, 2024 Net Loss Per Common Share The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock. The Company’s warrants, unvested restricted stock awards, and options are considered non-participating securities because holders are not The following is the calculation of the basic and diluted net loss per share of common stock for the three six July 31, 2024 2023 Three Months Ended Six Months Ended July 31, 2024 July 31, 2023 July 31, 2024 July 31, 2023 Basic and diluted loss per share: Net loss $ (2,803,000 ) $ (2,515,000 ) $ (5,542,000 ) $ (5,416,000 ) Basic and diluted net loss per share of common stock $ (0.05 ) $ (0.04 ) $ (0.09 ) $ (0.10 ) Weighted average shares outstanding – basic and diluted (1)(2) 60,110,178 56,357,684 59,167,134 56,164,282 ( 1 Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2024 2023 and 2,484,071 ( 2 Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three six July 31, 2024 three six July 31, 2023 Restructuring On October 16, 2023, one 2023. six July 31, 2024, (in thousands) As of July 31, 2024 Accrued Balance as of 2024 2024 Accrued Balance as of Total Costs Total January 31, 2024 Expenses to Date Cash Payments July 31, 2024 Incurred to Date Expected Costs Severance expense Cost of sales $ — $ — $ — $ — $ 154 $ 154 Selling, general, and administrative 74 — (74 ) — 350 350 Research and development — — — — 227 227 Total severance expense $ 74 $ — $ (74 ) $ — $ 731 $ 731 Professional fees — — — — 28 28 Total $ 74 $ — $ (74 ) $ — $ 759 $ 759 Non-Cash Items For the six July 31, 2024 2023, For the six July 31, 2024, second 5 2023 July 31, 2024), 7 not six July 31, 2023. Recent Accounting Pronouncements Not In November 2023, 2023 07, 280 2023 07 December 15, 2023, December 15, 2024. 2023 07 January 31, 2026. not In December 2023, 2023 09, 740 2023 09 December 15, 2024. not

Note 3 - Business Combination

Note 3 - Business Combination	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 3 — BUSINESS COMBINATION Avelead Acquisition The Company acquired all the equity interests of Avelead Consulting, LLC (“Avelead”) as part of the Company’s strategic expansion into the acute-care health care revenue cycle management industry (the “Transaction”). The Transaction was completed on August 16, 2021. As of January 31, 2024, second March 27, 2024, second three six July 31, 2024, second October 31, 2024. July 31, 2024

Note 4 - Operating Leases

Note 4 - Operating Leases	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 4 — OPERATING LEASES We determine whether an arrangement is a lease at inception. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not The Company has moved to a virtual office model and does not three six July 31, 2024 2023, Alpharetta Office Lease On October 1, 2021, third not not March 31, 2023. six July 31, 2024 2023, three July 31, 2024 2023. The Company entered into a lease for office space in Alpharetta, Georgia, on March 1, 2020. March 31, 2023. six July 31, 2024 2023, three July 31, 2024 2023. Suwanee Office Lease Upon acquiring Avelead on August 16, 2021 ( 3 one March 1, 2019, February 28, 2022. February 28, 2023, not six July 31, 2024 2023, three July 31, 2024 2023.

Note 5 - Debt

Note 5 - Debt	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 5 — DEBT Outstanding principal balances consisted of the following at July 31, 2024: July 31, 2024 January 31, 2024 Term loan $ 8,499,000 $ 9,000,000 Financing cost payable 164,000 135,000 Less: Deferred financing cost (52,000 ) (69,000 ) Total 8,611,000 9,066,000 Less: Current portion of term loan (2,000,000 ) (1,500,000 ) Non-current portion of term loan $ 6,611,000 $ 7,566,000 July 31, 2024 January 31, 2024 Notes payable and accrued interest $ 4,726,000 $ — Less: Discount on notes payable (721,000 ) — Less: Deferred financing costs (152,000 ) — Total 3,853,000 — Less: Current portion of notes payable — — Non-current portion of notes payable $ 3,853,000 $ — Term Loan and Revolving Line of Credit On November 29, 2022, August 26, 2026. no Under the Second Amended and Restated Loan Agreement, the Company has a term loan facility with an initial maximum principal amount of $10,000,000. Amounts outstanding under the Second Amended and Restated Loan Agreement bear interest at a per annum rate equal to the Prime Rate five August 2021). one second third fourth fifth may The Company executed a Third Modification and Waiver to Second Amended and Restated Loan Agreement (the “Third Modification”) and a Fourth Modification to Second Amended and Restated Loan Agreement (the “Fourth Modification”) on February 7, 2024 April 5, 2024, ● Minimum Adjusted EBITDA January 31, 2024, not no Minimum Quarter Ending Adjusted EBITDA January 31, 2024 $ (5,750,000 ) April 30, 2024 (4,560,000 ) July 31, 2024 (2,960,000 ) October 31, 2024 (1,500,000 ) January 31, 2025 430,000 ● Maximum ARR Net Leverage Ratio not Maximum ARR Net Leverage Quarter Ending Ratio April 30, 2024 0.50 1.00 July 31, 2024 0.45 1.00 October 31, 2024 0.40 1.00 January 31, 2025 0.35 1.00 ● Maximum Debt to Adjusted EBITDA Ratio April 30, 2025, four 4 not Maximum Debt to Adjusted EBITDA Quarter Ending Ratio April 30, 2025 3.50 1.00 July 31, 2025 3.00 1.00 October 31, 2025 2.50 1.00 January 31, 2026 and on the last day of each quarter thereafter 2.00 1.00 ● Fixed Charge Coverage Ratio April 30, 2025, not 1.00, four 4 The Second Amended and Restated Loan Agreement also includes customary negative covenants, subject to exceptions, which limit transfers, capital expenditures, indebtedness, certain liens, investments, acquisitions, dispositions of assets, restricted payments, and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including a cross default provision with the Second Amended and Restated Loan Agreement and a change of control default provision. The line of credit also is subject to customary prepayment requirements. Substantially all the assets of the Company are collateralized by the Second Amended and Restated Loan Agreement. As of July 31, 2024 may not 1 The Company records costs related to the maintenance of the Second Amended and Restated Loan Agreement as deferred financing costs, net of the term loan. These deferred financing costs are being amortized over the remaining term of the loan. The Company has incurred $250,000 in financing costs which become payable at the earlier of the term date of the loan, or pre-payment. These costs are being accreted, through interest expense, to the full value of the $250,000 over the remaining term of the loan. Debt Private Placement On February 1, 2024, February 7, 2024 ( Notes Payable The Notes bear interest at a rate of 15% per annum and mature on August 7, 2026 ( may twelve 12 twelve 12 The Notes also include customary negative covenants, subject to exceptions, which limit dispositions of assets and the business activities of the Company, as well as customary representations and warranties, affirmative covenants and events of default, including a cross default provision with the Second Amended and Restated Loan Agreement and a change of control default provision. The rights of each Investor to receive payments under the Notes are subordinate to the rights of Western Alliance Bank (“WAB”), pursuant to a subordination agreement which the Investors entered into with WAB concurrently with the Debt Private Placement. The Company allocated the original total proceeds at inception from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 Warrants The Warrants have an exercise price of $0.38 (except for Warrants issued to the Company’s directors and officers which have an exercise price of $0.39), are immediately exercisable, and will expire on the fourth The Notes and the Warrants described above were offered in a private placement under Section 4 2 1933, may not 501 The Warrants contain a registration rights provision for the Company to provide the Warrant holder with registered common stock upon their exercise of a Warrant. If the Company is not May 7, 2024, 3 No. 333 279190 No. 1 3 May 24, 2024 ( June 10, 2024. The Company allocated the total proceeds from the Debt Private Placement and Common Stock Private Placement (refer to Note 7 three July 31, 2024, $837,000

Note 6 - Income Taxes

Note 6 - Income Taxes	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 6 — INCOME TAXES Income tax expense was $0 for the six July 31, 2024 The Company has recorded $346,000 and $340,000 in reserves for uncertain tax positions as of July 31, 2024 January 31, 2024 The Company and its subsidiaries are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2020. January 31, 2019. no January 31, 2020; January 31, 2020, may

Note 7 - Equity

Note 7 - Equity	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Equity [Text Block]	NOTE 7 — EQUITY Common Stock Private Placement On February 6, 2024, The common stock described above was offered in a private placement under Section 4 2 not may not 501 The Company allocated the total proceeds of the Common Stock Private Placement across the underlying components. As a result, $77,000 of net proceeds, comprised of $81,000 of the proceeds less $4,000 of issuance costs, was recorded for the Common Stock Private Placement as equity. Registration of Shares Issued to 180 On June 28, 2023, 3 No. 333 272993 180 “180 July 10, 2023. On May 7, 2024, 3 No. 333 279190 No. 1 3 May 24, 2024, 180 June 10, 2024. 2024 At the 2024 June 13, 2024, 2024 “2024 2024 2013 “2013 2024 2024 The 2024 2024

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8 — COMMITMENTS AND CONTINGENCIES Consulting Agreement with 180 On March 19, 2020, 180 180 September 20, 2021, December 2023, two July 31, 2024, three 20 90 no may 121G “121G” 121G, 180 six July 31, 2024 2023, July 31, 2024 three July 31, 2024 2023, 180 131,054 180 three six July 31, 2024, 180 three six July 31, 2023, three six July 31, 2024, $38,000 three six July 31, 2023, 180 three six July 31, 2024, three six July 31, 2023, 180 Inclusive of the MSA executed with 180 180 121G. no 121G. 180 121G three six July 31, 2024 2023, Litigation We are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	6 Months Ended
	Jul. 31, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 Avelead Office Lease The Company acquired Avelead on August 16, 2021. one August 2023. February 2023. six July 31, 2024 2023, three July 31, 2024 2023. 3 Debt Private Placement The following related parties participated in the Debt Private Placement (Refer to Note 5 Name of Investor Investment Amount Warrants Granted 121G, LLC (1) $ 1,000,000 897,436 Matthew Etheridge (2) 1,000,000 921,053 Jonathan R. Phillips (3) 50,000 44,872 The Ferayorni Family Trust (4) 500,000 448,718 ( 1 121G, “121G” may 121G. ( 2 3 4 may Common Stock Private Placement On February 6, 2024,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jul. 31, 2024	Jul. 31, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5. During the three July 31, 2024 none 16a 1 1934, 10b5 1 10b5 1 408 1933
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jul. 31, 2024
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to the recognition of revenue, share-based compensation, capitalization of software development costs, intangible assets, the allowance for credit losses, contingent consideration, and income taxes. Actual results could differ from those estimates.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassification Certain amounts for the three six July 31, 2023 three six July 31, 2023, three six July 31, 2023
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Financial Accounting Standards Board’s (“FASB”) authoritative guidance on fair value measurements establishes a framework for measuring fair value. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one three Level 1: Level 2: Level 3: not The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. 3 April 30, 2024. The table below provides information on the fair value of our liabilities on a recurring basis: Quoted Significant Prices in Other Significant Active Observable Unobservable Total Fair Markets Inputs Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2024 Acquisition earnout liability (1) $ 1,794,000 $ — $ — $ 1,794,000 ( 1 On March 27, 2024, 3 no 3 3. The table below provides the Level 3 six July 31, 2024. no 3 three July 31, 2024. Six-months ended July 31, 2024 Beginning balance $ 1,794,000 Settlement – common stock (690,000 ) Settlement – cash (447,000 ) Realized loss 159,000 Transfer out (817,000 ) Ending balance $ — The value of the Company’s acquisition earnout liability at July 31, 2024, October 31, 2024. The fair value of the Company’s term loan under its Second Amended and Restated Loan and Security Agreement (as amended and modified, the “Second Amended and Restated Loan Agreement”) was determined through an analysis of the interest rate spread from the date of closing the loan ( August 2021) July 31, 2024 January 31, 2024 Prime Rate July 31, 2024 January 31, 2024, The estimated fair value of the Company’s notes payable under its private placement notes payables was determined through an analysis of the interest rate spread from the date of closing of the private placement ( February 7, 2024) July 31, 2024. 30 1 10 February 7, 2024 ( 30 July 31, 2024 The estimated fair value of the warrant liability is calculated using a Black-Scholes pricing model. The model input uses the warrant strike prices of $0.38 $0.39, February 7, 2024, April 30, 2024, May 7, 2024) 48 Using this methodology, the Company recorded an opening warrant liability of $881,000 as of February 7, 2024. April 30, 2024 May 7, 2024 three six July 31, 2024, May 7, 2024,
Revenue [Policy Text Block]	Revenue Recognition We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a SaaS delivery model, through the Company’s direct sales force or through third We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers may Disaggregation of Revenue The following table provides information about disaggregated revenue by type and nature of revenue stream: Three Months Ended Six Months Ended July 31, 2024 July 31, 2023 July 31, 2024 July 31, 2023 Over time revenue $ 4,476,000 $ 5,770,000 $ 8,672,000 $ 11,028,000 Point in time revenue — — 135,000 74,000 Total revenue $ 4,476,000 $ 5,770,000 $ 8,807,000 $ 11,102,000 The Company includes revenue categories of (i) over time and (ii) point in time revenue. The Company includes revenue categories of (i) SaaS, (ii) maintenance and support, (iii) professional services, and (iv) audit services as over time revenue. For point in time revenue, the performance obligation is recognized as the point in time when the obligation is fully satisfied. The Company includes software licenses as point in time revenue. Contract Receivables and Deferred Revenues The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not . During the three six July 31, 2024 , the Company recognized approximately $1,795,000 and $4,625,000, respectively, in revenue from deferred revenues outstanding as of January 31, 2024 . Revenue allocated to remaining performance obligations was $ as of July 31, 2024 , of which the Company expects to recognize approximately 43% over the next 12 months and the remainder thereafter. Deferred costs (costs to fulfill a contract and contract acquisition costs) The Company defers th e direct costs, which include salaries and benefits, for professional services related to SaaS contracts as a cost to fulfill a contract. These deferred costs will be amortized on a straight-line basis over the period of expected benefit which is the contractual term. As of July 31, 2024 and January 31, 2024 , the Company had deferred costs of $55,000 and $77,000, r on of $136,000 and $102,000, r s $33,000 and $34,000 fo six July 31, 2024 2023 three July 31, 2024 2023, Contract acquisition costs, which consist of sales commissions paid or payable, are considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over the contract term. As a practical expedient, the Company expenses sales commissions as incurred when the amortization period of related deferred commission costs is expected to be one As of July 31, 2024 and January 31, 2024 , deferred commission costs paid and payable, which are included on the consolidated balance sheets within other non-current assets totaled $1,279,000 and $1,461,000, respectively. Amortization expense associated with deferred sales commissions, which is included in selling, general and administrative expense in the condensed consolidated statements of operations, was $169,000 and $125,000 for the three July 31, 2024 2023 , respectively. For the six July 31, 2024 2023, Allowance for Credit Losses The Company estimates current expected credit losses based on historical credit loss rates and applied an increase to account for future economic conditions. The changes in the Company’s allowance for credit losses is as follows: January 31, 2024 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2024 Allowance for credit losses $ 86,000 $ — (58,000 ) 31,000 $ 59,000 January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2023 Allowance for credit losses $ 132,000 $ (36,000 ) $ — $ — $ 96,000
Share-Based Payment Arrangement [Policy Text Block]	Equity Awards The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period, and forfeitures are recognized as incurred. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the entity had paid cash for the goods or services. The Company incurred total compensation expense related to share-based awards for the three six July 31, 2024, three six July 31, 2023. The fair value of stock options granted are estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor and expected term). Future grants of equity awards accounted for as share-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards. The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market closing price per share on the grant date. For the three six July 31, 2024, three six July 31, 2023, three three six July 31, 2024, three six July 31, 2023, Market-Based Awards For awards with a market condition, the Company adjusts the grant date fair value for the condition. The Company used separate Monte Carlo valuation models, as of the grant date, to determine the expected length and fair value of this particular award. Both models used the Company's historical equity volatility, current stock price, and hurdle target price for vesting. The service period model also included an assumption for the Company's 10 On July 18, 2024,
Derivatives, Policy [Policy Text Block]	Warrants The Company reviews the specific terms for its warrants and applies the authoritative FASB guidance under ASC topics 480 , 480” 815 , 815” 480 , 480 , 815 , For the issued or modified warrants that qualify for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not
Income Tax, Policy [Policy Text Block]	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not not not not 6 The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not July 31, 2024
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Common Share The Company presents basic and diluted earnings per share (“EPS”) data for the Company’s common stock. The Company’s warrants, unvested restricted stock awards, and options are considered non-participating securities because holders are not The following is the calculation of the basic and diluted net loss per share of common stock for the three six July 31, 2024 2023 Three Months Ended Six Months Ended July 31, 2024 July 31, 2023 July 31, 2024 July 31, 2023 Basic and diluted loss per share: Net loss $ (2,803,000 ) $ (2,515,000 ) $ (5,542,000 ) $ (5,416,000 ) Basic and diluted net loss per share of common stock $ (0.05 ) $ (0.04 ) $ (0.09 ) $ (0.10 ) Weighted average shares outstanding – basic and diluted (1)(2) 60,110,178 56,357,684 59,167,134 56,164,282 ( 1 Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2024 2023 and 2,484,071 ( 2 Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three six July 31, 2024 three six July 31, 2023
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]	Restructuring On October 16, 2023, one 2023. six July 31, 2024, (in thousands) As of July 31, 2024 Accrued Balance as of 2024 2024 Accrued Balance as of Total Costs Total January 31, 2024 Expenses to Date Cash Payments July 31, 2024 Incurred to Date Expected Costs Severance expense Cost of sales $ — $ — $ — $ — $ 154 $ 154 Selling, general, and administrative 74 — (74 ) — 350 350 Research and development — — — — 227 227 Total severance expense $ 74 $ — $ (74 ) $ — $ 731 $ 731 Professional fees — — — — 28 28 Total $ 74 $ — $ (74 ) $ — $ 759 $ 759
Noncash Investing and Financing Activities [Policy Text Block]	Non-Cash Items For the six July 31, 2024 2023, For the six July 31, 2024, second 5 2023 July 31, 2024), 7 not six July 31, 2023.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Not In November 2023, 2023 07, 280 2023 07 December 15, 2023, December 15, 2024. 2023 07 January 31, 2026. not In December 2023, 2023 09, 740 2023 09 December 15, 2024. not

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jul. 31, 2024
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Quoted Significant Prices in Other Significant Active Observable Unobservable Total Fair Markets Inputs Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2024 Acquisition earnout liability (1) $ 1,794,000 $ — $ — $ 1,794,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Six-months ended July 31, 2024 Beginning balance $ 1,794,000 Settlement – common stock (690,000 ) Settlement – cash (447,000 ) Realized loss 159,000 Transfer out (817,000 ) Ending balance $ —
Disaggregation of Revenue [Table Text Block]	Three Months Ended Six Months Ended July 31, 2024 July 31, 2023 July 31, 2024 July 31, 2023 Over time revenue $ 4,476,000 $ 5,770,000 $ 8,672,000 $ 11,028,000 Point in time revenue — — 135,000 74,000 Total revenue $ 4,476,000 $ 5,770,000 $ 8,807,000 $ 11,102,000
Accounting Standards Update and Change in Accounting Principle [Table Text Block]	January 31, 2024 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2024 Allowance for credit losses $ 86,000 $ — (58,000 ) 31,000 $ 59,000 January 31, 2023 CECL Adoption Provision adjustments Write-offs & Recoveries July 31, 2023 Allowance for credit losses $ 132,000 $ (36,000 ) $ — $ — $ 96,000
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Six Months Ended July 31, 2024 July 31, 2023 July 31, 2024 July 31, 2023 Basic and diluted loss per share: Net loss $ (2,803,000 ) $ (2,515,000 ) $ (5,542,000 ) $ (5,416,000 ) Basic and diluted net loss per share of common stock $ (0.05 ) $ (0.04 ) $ (0.09 ) $ (0.10 ) Weighted average shares outstanding – basic and diluted (1)(2) 60,110,178 56,357,684 59,167,134 56,164,282
Restructuring and Related Costs [Table Text Block]	(in thousands) As of July 31, 2024 Accrued Balance as of 2024 2024 Accrued Balance as of Total Costs Total January 31, 2024 Expenses to Date Cash Payments July 31, 2024 Incurred to Date Expected Costs Severance expense Cost of sales $ — $ — $ — $ — $ 154 $ 154 Selling, general, and administrative 74 — (74 ) — 350 350 Research and development — — — — 227 227 Total severance expense $ 74 $ — $ (74 ) $ — $ 731 $ 731 Professional fees — — — — 28 28 Total $ 74 $ — $ (74 ) $ — $ 759 $ 759

Note 5 - Debt (Tables)

Note 5 - Debt (Tables)	6 Months Ended
	Jul. 31, 2024
Notes Tables
Schedule of Debt [Table Text Block]	July 31, 2024 January 31, 2024 Term loan $ 8,499,000 $ 9,000,000 Financing cost payable 164,000 135,000 Less: Deferred financing cost (52,000 ) (69,000 ) Total 8,611,000 9,066,000 Less: Current portion of term loan (2,000,000 ) (1,500,000 ) Non-current portion of term loan $ 6,611,000 $ 7,566,000 July 31, 2024 January 31, 2024 Notes payable and accrued interest $ 4,726,000 $ — Less: Discount on notes payable (721,000 ) — Less: Deferred financing costs (152,000 ) — Total 3,853,000 — Less: Current portion of notes payable — — Non-current portion of notes payable $ 3,853,000 $ —
Schedule Of Minimum Adjusted EBITDA [Table Text Block]	Minimum Quarter Ending Adjusted EBITDA January 31, 2024 $ (5,750,000 ) April 30, 2024 (4,560,000 ) July 31, 2024 (2,960,000 ) October 31, 2024 (1,500,000 ) January 31, 2025 430,000
Schedule of Debt to APR Ratios [Table Text Block]	Maximum ARR Net Leverage Quarter Ending Ratio April 30, 2024 0.50 1.00 July 31, 2024 0.45 1.00 October 31, 2024 0.40 1.00 January 31, 2025 0.35 1.00
Schedule of Debt, Adjusted EBITDA [Table Text Block]	Maximum Debt to Adjusted EBITDA Quarter Ending Ratio April 30, 2025 3.50 1.00 July 31, 2025 3.00 1.00 October 31, 2025 2.50 1.00 January 31, 2026 and on the last day of each quarter thereafter 2.00 1.00

Note 9 - Related Party Transa_2

Note 9 - Related Party Transactions (Tables)	6 Months Ended
	Jul. 31, 2024
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Name of Investor Investment Amount Warrants Granted 121G, LLC (1) $ 1,000,000 897,436 Matthew Etheridge (2) 1,000,000 921,053 Jonathan R. Phillips (3) 50,000 44,872 The Ferayorni Family Trust (4) 500,000 448,718

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual)	6 Months Ended
	Jul. 31, 2024 USD ($)	Jan. 31, 2024 USD ($)
Number of Operating Segments	1
Number of Reportable Segments	1
Long-Term Debt	$ 8,611,000	$ 9,066,000
Term Loan [Member]
Long-Term Debt	12,400,000
Long-Term Debt, Current Maturities	$ 2,000,000	$ 1,500,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies 1 (Details Textual)						3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 18, 2024 $ / shares shares	May 07, 2024 USD ($)	Mar. 27, 2024 USD ($)	Oct. 16, 2023 USD ($)	Nov. 29, 2022	Jul. 31, 2024 USD ($) shares	Jul. 31, 2023 USD ($) shares	Jul. 31, 2024 USD ($) shares	Jul. 31, 2023 USD ($) shares	Jan. 31, 2023 USD ($)	Apr. 30, 2024	Feb. 07, 2024 USD ($)	Jan. 31, 2024 USD ($)
Business Combination, Acquisition Related Costs							$ 9,000		$ 44,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			$ 159,000
Business Combination, Contingent Consideration, Liability, Current						$ 577,000		$ 577,000					$ 1,794,000
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]					Prime Rate [Member]			Prime Rate [Member]
Contract with Customer, Liability, Revenue Recognized						1,795,000		$ 4,625,000
Revenue, Remaining Performance Obligation, Amount						31,039,000		31,039,000
Deferred Costs						55,000		55,000					77,000
Accumulated Amortization of Other Deferred Costs						136,000		136,000					102,000
Amortization of Deferred Charges						13,000	17,000	33,000	34,000
Deferred Commission Costs Paid and Payable						1,279,000		1,279,000					1,461,000
Amortization of Deferred Sales Commissions						169,000	125,000	310,000	254,000
Share-Based Payment Arrangement, Expense						533,000	$ 537,000	$ 1,032,000	$ 1,109,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares								3,467,600	2,484,071
Restructuring and Related Cost, Number of Positions Eliminated				26
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent				24%
Restructuring Costs				$ 759,000		$ 0
Stock Issued								$ 67,000	$ 116,000
Professional Fees, Noncash								$ 4,000
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares								66,000	618,958
Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares								3,467,600	2,484,071
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares								3,555,499
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | shares						0	0	1,015,000	1,085,000
Restricted Stock [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | shares						1,500,000	258,621	1,700,000	458,621
Restricted Stock [Member] | Executive Chairman [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | shares	200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Price (in dollars per share) | $ / shares	$ 1.75
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Payment Arrangement, Expense						$ 38,000	$ 93,000	$ 67,000	$ 116,000
Common Stock Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings						$ (91,000)		$ 44,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3		$ 837,000
Common Stock Warrant [Member]
Warrants and Rights Outstanding												$ 881,000
Measurement Input, Exercise Price [Member] | Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input		0.33									0.3	0.34
Measurement Input, Exercise Price [Member] | Minimum [Member] | Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input						0.38		0.38
Measurement Input, Exercise Price [Member] | Maximum [Member] | Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input						0.39		0.39
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input						0.04		0.04
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input						0.05		0.05
Measurement Input, Price Volatility [Member] | Minimum [Member] | Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input						0.91		0.91
Measurement Input, Price Volatility [Member] | Maximum [Member] | Common Stock Warrant [Member]
Warrants and Rights Outstanding, Measurement Input						0.92		0.92
Term Loan and Revolving Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate								1.50%
Debt Instrument, Basis Rate Floor								3.25%
Debt Instrument, Increase (Decrease) in Basis Spread on Variable Rate								0.50%
Debt Instrument, Fair Value Disclosure						$ 8,314,000		$ 8,314,000					8,807,000
Debt Instrument, Unamortized Discount						186,000		186,000					193,000
Debt Issuance Costs, Net						52,000		$ 52,000					$ 69,000
Private Placement Notes [Member]
Debt Instrument, Increase (Decrease) in Basis Spread on Variable Rate								0.23%
Debt Instrument, Fair Value Disclosure						3,847,000		$ 3,847,000
Debt Instrument, Unamortized Discount						5,000		5,000
Unsecured Subordinated Promissory Notes [Member]
Debt Instrument, Fair Value Disclosure						3,538,000		3,538,000
Debt Instrument, Unamortized Discount						862,000		862,000
Debt Issuance Costs, Net						102,000		102,000
Payments of Debt Issuance Costs										$ 20,000
Debt Issuance Costs, Noncurrent, Net						82,000		82,000
Avelead Acquisition [Member]
Business Combination, Contingent Consideration, Liability, Current						$ 577,000		577,000
Avelead Acquisition [Member] | Common Stock [Member] | Second Earnout [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable								690,000
Avelead Acquisition [Member] | Warrant 1 [Member] | Second Earnout [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable								$ 881,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-08-01	Jul. 31, 2024
Revenue, Remaining Performance Obligation, Percentage	43%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	12 months

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Fair Value of Liabilities (Details) - Fair Value, Recurring [Member]	Jan. 31, 2024 USD ($)	[1]
Acquisition earnout liability (1)	$ 1,794,000
Fair Value, Inputs, Level 1 [Member]
Acquisition earnout liability (1)	0
Fair Value, Inputs, Level 2 [Member]
Acquisition earnout liability (1)	0
Fair Value, Inputs, Level 3 [Member]
Acquisition earnout liability (1)	$ 1,794,000
[1]On March 27, 2024, the Company issued the shares of its common stock owed as part of the acquisition earnout liability related to the acquisition of Avelead Consulting, LLC (“Avelead”). The remaining obligation related to the acquisition earnout liability is to be settled in cash (refer to Note 3 – Business Combinations for more information). At that time, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was removed from the hierarchy. As of that date, the Company recorded a valuation adjustment of $159,000 using the value of the shares issued adjusted for a discount for lack of marketability. As of April 30, 2024, the acquisition earnout liability no longer qualified as a Level 3 fair value calculation and was transferred out. See the table below for the roll-forward of values including the amount transitioned out of Level 3.

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Acquisition Earnout Liability Rollforward (Details) - Earn Out Liability [Member]	6 Months Ended
	Jul. 31, 2024 USD ($)
Beginning balance	$ 1,794,000
Settlement – common stock	(690,000)
Settlement – cash	(447,000)
Realized loss	159,000
Transfer out	(817,000)
Ending balance	$ 0

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Total revenues	$ 4,476,000	$ 5,770,000	$ 8,807,000	$ 11,102,000
Transferred over Time [Member]
Total revenues	4,476,000	5,770,000	8,672,000	11,028,000
Transferred at Point in Time [Member]
Total revenues	$ 0	$ 0	$ 135,000	$ 74,000

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Accounting Standards Update (Details) - USD ($)	6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Allowance for credit losses	$ 86,000	$ 132,000
Allowance for credit losses, provision	(58,000)	0
Allowance for credit losses, writeoffs	31,000	0
Allowance for credit losses	59,000	96,000
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2016-13 [Member]
Allowance for credit losses	$ 0	$ (36,000)

Note 2 - Summary of Significa_9

Note 2 - Summary of Significant Accounting Policies - Schedule of Earnings Per Share (Details) - USD ($)		3 Months Ended				6 Months Ended
		Jul. 31, 2024	Apr. 30, 2024	Jul. 31, 2023	Apr. 30, 2023	Jul. 31, 2024	Jul. 31, 2023
Net loss		$ (2,803,000)	$ (2,739,000)	$ (2,515,000)	$ (2,901,000)	$ (5,542,000)	$ (5,416,000)
Net loss per common share – basic and diluted (in dollars per share)		$ (0.05)		$ (0.04)		$ (0.09)	$ (0.1)
Weighted average number of common shares – basic and diluted (in shares)	[1],[2]	60,110,178		56,357,684		59,167,134	56,164,282
[1]Diluted net loss per share excludes the effect of shares that are anti-dilutive. For the three and six months ended July 31, 2024, diluted earnings per share excludes 66,000 outstanding stock options, 3,467,600 unvested restricted shares of common stock, and 3,555,499 shares of common stock issuable through the exercise of warrants. For the three and six months ended July 31, 2023, diluted earnings per share excludes 618,958 outstanding stock options and 2,484,071 unvested restricted shares of common stock.[2]Includes the effect of vested and excludes the effect of unvested restricted shares of common stock, which are considered non-participating securities. As of July 31, 2024 and 2023, there were 3,467,600 and 2,655,831 unvested restricted shares of common stock outstanding, respectively.

Note 2 - Summary of Signific_10

Note 2 - Summary of Significant Accounting Policies - Schedule of Restructuring Information (Details) $ in Thousands	6 Months Ended
	Jul. 31, 2024 USD ($)
Restructuring reserve	$ 74
Restructuring charges	0
Restructuring payments	(74)
Restructuring reserve	0
Restructuring costs incurred	759
Expected restructuring costs	759
Employee Severance Allocated to Cost of Sales [Member]
Restructuring reserve	0
Restructuring charges	0
Restructuring payments	0
Restructuring reserve	0
Restructuring costs incurred	154
Expected restructuring costs	154
Employee Severance Allocated to Selling, General, and Administrative [Member]
Restructuring reserve	74
Restructuring charges	0
Restructuring payments	(74)
Restructuring reserve	0
Restructuring costs incurred	350
Expected restructuring costs	350
Employee Severance Allocated to Research and Development [Member]
Restructuring reserve	0
Restructuring charges	0
Restructuring payments	0
Restructuring reserve	0
Restructuring costs incurred	227
Expected restructuring costs	227
Employee Severance [Member]
Restructuring reserve	74
Restructuring charges	0
Restructuring payments	(74)
Restructuring reserve	0
Restructuring costs incurred	731
Expected restructuring costs	731
Professional Fees and Licenses [Member]
Restructuring reserve	0
Restructuring charges	0
Restructuring payments	0
Restructuring reserve	0
Restructuring costs incurred	28
Expected restructuring costs	$ 28

Note 3 - Business Combination (

Note 3 - Business Combination (Details Textual) - USD ($)		3 Months Ended	6 Months Ended
	Mar. 27, 2024	Jul. 31, 2024	Jul. 31, 2024	Jan. 31, 2024
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.01	$ 0.01	$ 0.01
Business Combination, Contingent Consideration, Liability, Current		$ 577,000	$ 577,000	$ 1,794,000
Avelead Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	1,589,386
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01
Payments to Acquire Businesses, Gross		240,000	687,000
Business Combination, Contingent Consideration, Liability, Current		$ 577,000	$ 577,000
Avelead Acquisition [Member] | Earn Out Liability [Member]
Business Combination, Contingent Consideration, Liability				$ 1,794,000

Note 4 - Operating Leases (Deta

Note 4 - Operating Leases (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		18 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Mar. 31, 2023	Oct. 01, 2021	Aug. 16, 2021	Mar. 01, 2020
Membership Agreements and Daily Space Rentals [Member]
Operating Lease, Expense	$ 9,000	$ 6,000	$ 17,000	$ 10,000
Alpharetta Sublease [Member]
Lessor, Operating Lease, Term of Contract (Month)						18 months
Sublease Income	0	0	0	32,000	$ 292,000
Alpharetta Office Lease [Member]
Operating Lease, Right-of-Use Asset								$ 540,000
Lessee, Operating Lease, Discount Rate								6.50%
Operating Lease, Cost	0	0	0	32,000
Suwanee Office Lease [Member]
Operating Lease, Expense	$ 0	$ 0	$ 0	$ 6,000
Lessee, Operating Lease, Term of Contract (Month)							36 months
Lessee, Operating Lease, Renewal Term (Month)							12 months

Note 5 - Debt (Details Textual)

Note 5 - Debt (Details Textual)		3 Months Ended	6 Months Ended
	Nov. 29, 2022 USD ($)	Apr. 30, 2024 USD ($)	Jul. 31, 2024 USD ($) $ / shares	May 24, 2024 shares	Feb. 01, 2024 USD ($) shares	Jan. 31, 2024 USD ($)
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	Prime Rate [Member]		Prime Rate [Member]
Common Stock Warrant [Member]
Derivative Liability					$ 881,000
Professional Fees		$ 46,000
Maximum [Member]
Common Stock, Shares, Outstanding, Percent			9.99%
Non Directors and Officers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.38
Directors and Officers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.39
Securities Purchase Agreement February 2024 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					4,016,025
Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares				4,016,025
Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Rate Floor	3.25%
Debt Instrument, Face Amount	$ 10,000,000
Debt Instrument, Term (Year)	5 years
Long-Term Debt, Maturity, Year Two			$ 500,000
Long-Term Debt, Maturity, Year Three			1,000,000
Long-Term Debt, Maturity, Year Four			2,000,000
Long-Term Debt, Maturity, Year Five			$ 3,000,000
Term Loan and Revolving Line of Credit [Member]
Debt Instrument, Basis Spread on Variable Rate			1.50%
Debt Instrument, Basis Rate Floor			3.25%
Debt Instrument, Covenant, Fixed Charge Coverage Ratio			1.2
Amortization of Debt Issuance Costs			$ 250,000
Debt Instrument, Fair Value Disclosure			8,314,000			$ 8,807,000
Debt Instrument, Unamortized Discount			186,000			$ 193,000
Unsecured Subordinated Promissory Notes [Member]
Debt Instrument, Face Amount			4,400,000
Debt Instrument, Interest Rate, Effective Percentage					15%
Debt Instrument, Fair Value Disclosure			3,538,000
Debt Instrument, Unamortized Discount			862,000
Debt Issuance Costs, Gross			$ 183,000
Unsecured Subordinated Promissory Notes [Member] | Securities Purchase Agreement February 2024 [Member]
Debt Instrument, Face Amount					$ 4,400,000
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,000,000
Debt Instrument, Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Rate Floor	3.25%

Note 5 - Debt - Schedule of Out

Note 5 - Debt - Schedule of Outstanding Debt (Details) - USD ($)	Jul. 31, 2024	Jan. 31, 2024
Total	$ 8,611,000	$ 9,066,000
Total	3,853,000	0
Less: Current portion of notes payable	0	0
Non-current portion of notes payable	3,853,000	0
Revolving Credit Facility [Member]
Long term debt, gross	164,000	135,000
Notes payable and accrued interest	164,000	135,000
Note Payable [Member[
Long term debt, gross	4,726,000	0
Less: Deferred financing cost	(152,000)	0
Notes payable and accrued interest	4,726,000	0
Less: Discount on notes payable	(721,000)	0
Term Loan [Member]
Long term debt, gross	8,499,000	9,000,000
Total	12,400,000
Less: Current portion of term loan	(2,000,000)	(1,500,000)
Total non-current portion of debt	6,611,000	7,566,000
Notes payable and accrued interest	8,499,000	9,000,000
Term Loan and Revolving Line of Credit [Member]
Less: Deferred financing cost	(52,000)	(69,000)
Less: Discount on notes payable	$ (186,000)	$ (193,000)

Note 5 - Debt - Schedule of Min

Note 5 - Debt - Schedule of Minimum Adjusted EBITDA (Details) - USD ($)	Jan. 31, 2025	Oct. 31, 2024	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024
Minimum Adjusted EBITDA			$ (2,960,000)	$ (4,560,000)	$ (5,750,000)
Forecast [Member]
Minimum Adjusted EBITDA	$ 430,000	$ (1,500,000)

Note 6 - Income Taxes (Details

Note 6 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Jan. 31, 2024
Income Tax Expense (Benefit)	$ 0	$ 8,000	$ 0	$ 61,000
Effective Income Tax Rate Reconciliation, Percent			0%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			24%
Unrecognized Tax Benefits	$ 346,000		$ 346,000		$ 340,000

Note 7 - Equity (Details Textua

Note 7 - Equity (Details Textual) - USD ($)				3 Months Ended
	May 24, 2024	Feb. 06, 2024	Jun. 28, 2023	Apr. 30, 2024	Jun. 13, 2024
The 2024 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)					6,738,902
180 Consulting [Member]
Stock Issued During Period, Shares, New Issues (in shares)	564,707		394,127
Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)		263,158
Sale of Stock, Price Per Share (in dollars per share)		$ 0.38
Sale of Stock, Consideration Received on Transaction		$ 100,000
Net Proceeds from Issuance of Private Placement				$ 77,000
Proceeds from Issuance of Private Placement				81,000
Payments of Stock Issuance Costs				$ 4,000

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual) - 180 Consulting [Member] - Master Services Agreement [Member] - USD ($)	3 Months Ended		6 Months Ended		52 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024
Stock Issued During Period, Shares, Issued for Services (in shares)	398,365	131,054	817,018	258,153	2,296,925
Professional Fees	$ 760,000	$ 966,000	$ 1,323,000	$ 1,919,000
Share-Based Payment Arrangement, Amount Capitalized	38,000	93,000	67,000	116,000
Payments for Other Fees	264,000	719,000	640,000	1,727,000
Statements of Work Under Sublease [Member]
Payments for Other Fees	$ 82,000	$ 264,000	$ 223,000	$ 381,000

Note 9 - Related Party Transa_3

Note 9 - Related Party Transactions (Details Textual) - USD ($)				3 Months Ended			6 Months Ended
		Feb. 07, 2024	Feb. 06, 2024	Jul. 31, 2024	Apr. 30, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Stock Issued During Period, Value, New Issues				$ 0	$ 770,000
Matthew Etheridge [Member]
Related Party Transaction, Amounts of Transaction	[1]	$ 1,000,000
Matthew Etheridge [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)			263,158
Shares Issued, Price Per Share (in dollars per share)			$ 0.38
Stock Issued During Period, Value, New Issues			$ 100,000
Rent Expense [Member] | Former Employee of Avelead [Member]
Related Party Transaction, Amounts of Transaction				$ 0		$ 0	$ 0	$ 6,000
[1]Mr. Etheridge became a member of the Company’s Board of Directors subsequent to the closing of the Debt Private Placement.

Note 9 - Related Party Transa_4

Note 9 - Related Party Transactions - Schedule of Related Party Transactions (Details)	Feb. 07, 2024 USD ($) shares
Wyche Tee Green III [Member]
Related party transactions | $	$ 1,000,000	[1]
Wyche Tee Green III [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Warrants Granted (in shares) | shares	897,436	[1]
Matthew Etheridge [Member]
Related party transactions | $	$ 1,000,000	[2]
Matthew Etheridge [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Warrants Granted (in shares) | shares	921,053	[2]
Jonathan R Phillips [Member]
Related party transactions | $	$ 50,000	[3]
Jonathan R Phillips [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Warrants Granted (in shares) | shares	44,872	[3]
Justin J Ferayorni [Member]
Related party transactions | $	$ 500,000	[4]
Justin J Ferayorni [Member] | Class of Warrant or Right, Securities Purchase Agreement February 2024 [Member]
Warrants Granted (in shares) | shares	448,718	[4]
[1]The securities held in the account of 121G, LLC (“121G”) may be deemed to be beneficially owned by Wyche “Tee” Green, III, the managing member of 121G. Mr. Green serves as Executive Chairman of the Company and is a member of the Company’s Board of Directors.[2]Mr. Etheridge became a member of the Company’s Board of Directors subsequent to the closing of the Debt Private Placement.[3]Mr. Phillips is a member of the Company’s Board of Directors.[4]The securities held in the account of The Ferayorni Family Trust may be deemed to be beneficially owned by Justin J. Ferayorni as co-trustee of The Ferayorni Family Trust. Mr. Ferayorni is a member of the Company’s board of directors.